ENGLISH
|
HINDI
APPS
iPhone
|
iPad
|
BlackBerry
|
Android
Nokia
Windows
Network18
Quotes
Quotes
NAVs
News
Messages
People
Notices
Videos
All
FEEDBACK
Facebook
Follow @moneycontrolcom on Twitter
CNBC TV 18
moneycontrol
News
Markets
Mutual Funds
IPO
Commodities
Wealth
Portfolio
Messages
My TV
Tax
Fixed Income
Property
SME
CNBC-TV18
Home
Business
General News
Market Trends
Stocks
Fund News
Personal Finance
Corporate Strategy
Lifestyle
Politics
Legal
Master Your Money
Share
>
Share
Tweet
Share on Tumblr
Intas Biopharmaceuticals
News »
latest
by relevance
IBPL- Apotex to develop biosimilar version of pegfilgrastim
Feb 06, 2009 at 16:18
Apotex Inc. of Canada and Intas Biopharmaceuticals Limited of India have extended their business agreement to develop a biosimilar version of pegfilgrastim, a protein that is used to treat neutropenia (a side effect of cancer chemotherapy).
CBL & GE Healthcare to set up Plasma Fractionation facility
Jan 23, 2009 at 16:11
Celestial Biologicals Collaborates with GE Healthcare to set up Indias First fully integrated Chromatography based Plasma Fractionation Facility
IBPL plans manufacturing facility for Monoclonal Antibodies
Jan 16, 2009 at 15:09
Intas Biopharmaceuticals Limited, Indias leading biotechnology company, signed a Memorandum of Understanding (MoU) with Government of Gujarat for setting up a separate manufacturing facility for Monoclonal Antibodies (MAbs), a recombinant mammalian platform product.
IBM DB2 continues to gain momentum in SMB mkt in India
Jan 13, 2009 at 13:40
IBM announced new IBM DB2 client agreements in India, reflecting the rapid DB2 business growth since the latest release of the product was launched in the market last year. This growth was led by strong demand for IBM DB2 9 as the preferred database platform for SAP implementations in the mid-market in 2008.
Intas Biopharma acquires BPD Inc
Jun 20, 2008 at 17:29
Intas Biopharmaceuticals Limited has acquired US-based biotechnology corporation, Biologics Process Development Incorporated (BPD Inc.), based in Poway, California
Intas Biopharma to market lung cancer drug GEFITINIB
May 26, 2008 at 15:30
Intas Biopharmaceuticals Limited is all set to market Lung Cancer drug, GEFITINIB, under brand name GEFFY, in Indian market. In line with companys sales strategy to market novel targeted therapies, Intas Biopharmaceuticals will market GEFFY for treatment of Lung cancer especially non-small cell lung cancer
IBPL- Apotex to develop biosimilar version of pegfilgrastim
Feb 06, 2009 at 16:18
Apotex Inc. of Canada and Intas Biopharmaceuticals Limited of India have extended their business agreement to develop a biosimilar version of pegfilgrastim, a protein that is used to treat neutropenia (a side effect of cancer chemotherapy).
CBL & GE Healthcare to set up Plasma Fractionation facility
Jan 23, 2009 at 16:11
Celestial Biologicals Collaborates with GE Healthcare to set up Indias First fully integrated Chromatography based Plasma Fractionation Facility
IBPL plans manufacturing facility for Monoclonal Antibodies
Jan 16, 2009 at 15:09
Intas Biopharmaceuticals Limited, Indias leading biotechnology company, signed a Memorandum of Understanding (MoU) with Government of Gujarat for setting up a separate manufacturing facility for Monoclonal Antibodies (MAbs), a recombinant mammalian platform product.
IBM DB2 continues to gain momentum in SMB mkt in India
Jan 13, 2009 at 13:40
IBM announced new IBM DB2 client agreements in India, reflecting the rapid DB2 business growth since the latest release of the product was launched in the market last year. This growth was led by strong demand for IBM DB2 9 as the preferred database platform for SAP implementations in the mid-market in 2008.
Intas Biopharma acquires BPD Inc
Jun 20, 2008 at 17:29
Intas Biopharmaceuticals Limited has acquired US-based biotechnology corporation, Biologics Process Development Incorporated (BPD Inc.), based in Poway, California
Intas Biopharma to market lung cancer drug GEFITINIB
May 26, 2008 at 15:30
Intas Biopharmaceuticals Limited is all set to market Lung Cancer drug, GEFITINIB, under brand name GEFFY, in Indian market. In line with companys sales strategy to market novel targeted therapies, Intas Biopharmaceuticals will market GEFFY for treatment of Lung cancer especially non-small cell lung cancer
Photos »
/
Follow moneycontrol.com
Facebook
Twitter
Google Plus
RSS
Wap SMS
SMS
Alert
iPad
iPhone
Blackberry
OVI
Android
Window